關鍵字
 
Q W E R T Y U I O P
A S D F G H J K L
Z X C V B N M
首頁
  略過巡覽連結登入系統 / 首頁 / 消息內容 檢驗醫學科網站 檢驗通告 檢體採集原則


2.
自2019年10月1日起,異動檢驗項目ANA抗核抗體(FSIANA)報告欄位名稱及參考值
 2019.09.27

檢驗醫學部通知

   檢字10834

  期:2019927

受文者:彰基體系醫護及醫事同工

  旨:異動檢驗項目ANA抗核抗體(FSIANA)報告欄位名稱及參考值

  明:

1.     檢驗項目ANA抗核抗體適應症為協助臨床診斷自體免疫疾病。使用Hep-2細胞以間接免疫螢光分析法檢測ANA,為臨床實驗室常用且為已知之ANA測定標準方法。目前依據螢光形態報告欄位名稱如下Homogeneous pattern, Fine speckled pattern, Coarse speckled pattern, Centromere pattern, Nucleolar pattern, Peripheral pattern, PCNA pattern, Cytoplasmic staining pattern, Anti-nuclear mitotic apparatus -1 antibody pattern, Anti-nuclear mitotic apparatus -2 antibody pattern, Nuclear dots pattern, Centrioles pattern.

2.     2015年國際(International Consensus on Antinuclear Antibody (ANA) Patterns, ICAP)已對HEp-2細胞間接免疫螢光測定中觀察到的形態建立共識。本院參考ICAP2019年美國風濕病學會對SLE診斷的建議(2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for SystemicLupus Erythematosus)(Arthritis & Rheumatology Vol. 71, No. 9, September 2019, pp 1400–1412)及與臨床醫師諮詢討論檢驗流程,自2019101日起,ANA檢驗起始稀釋步驟由1:40異動為1:80,螢光形態及報告欄位名稱將依據ICAP國際共識建議,修訂如下

 

報告欄位

報告子欄位名稱

1

Non-reactive (AC0)

2

Nuclear homogeneous (AC1)

3

Nuclear dense fine speckled (AC2)

4

Centromere (AC3)

5

Nuclear fine speckled (AC4)

6

Nuclear large/coarse speckled (AC5)

7

Multiple nuclear dots (AC6)

8

Few nuclear dots (AC7)

9

Homogeneous nucleolar (AC8)

10

Clumpy nucleolar (AC9)

11

Punctate nucleolar (AC10)

12

Smooth nuclear envelope (AC11)

13

Punctate nuclear envelope (AC12)

14

PCNA-like (AC13)

15

CENP-F-like (AC14)

16

Cytoplasmic fibrilliar linear (AC15)

17

Cytoplasmic fibrilliar filamentous (AC16)

18

Cytoplasmic fibrillar segmental (AC17)

19

Cytoplasmic discrete dots/GW-body like (AC18)

20

Cytoplasmic dense fine speckled (AC19)

21

Cytoplasmic fine speckled (AC20)

22

Cytoplasmic reticular/AMA (AC21)

23

Polar/Golgi-like (AC22)

24

Rods and rings (AC23)

25

Centrosome (AC24)

26

Spindle fiber(AC25)

27

NuMA-like (AC26)

28

Intercellular bridge (AC27)

29

Mitotic chromosomal envelope (AC28)

30

Topo I-like (AC29)

31

Unclassfied nuclear pattern

32

Unclassfied cytoplasmic pattern

33

Unclassfied mitotic pattern

 

3. 參考值異動如下

(1)  Negative: titer <1:80

(2)  A high titer(1:160) is a significant disease indicator

4. 相關問題,請聯絡檢驗醫學部主任醫檢師鄭敏琳,分機5940

 

 

 

 

 

 

 

 

 

檢驗醫學部主任 林正修



 
  財團法人彰化基督教醫院 無標題文件
網站瀏覽人數:3522730   線上人數:32